Inovio Pharmaceuticals (NASDAQ:INO) Now Covered by Stephens (2024)

Stephens began coverage on shares of Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) in a report issued on Tuesday, Marketbeat reports. The brokerage set an “overweight” rating and a $20.00 price target on the biopharmaceutical company’s stock. Stephens’ price objective would suggest a potential upside of 53.02% from the stock’s previous close.

A number of other research analysts have also issued reports on INO. Oppenheimer raised shares of Inovio Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a research note on Thursday, January 25th. StockNews.com lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating on shares of Inovio Pharmaceuticals in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $70.67.

Read Our Latest Stock Report on INO

Inovio Pharmaceuticals Trading Up 14.4 %

Shares of Inovio Pharmaceuticals stock opened at $13.07 on Tuesday. Inovio Pharmaceuticals has a twelve month low of $3.89 and a twelve month high of $14.75. The business’s 50 day simple moving average is $11.36 and its 200-day simple moving average is $36.81.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last issued its earnings results on Monday, May 13th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.23). Inovio Pharmaceuticals had a negative return on equity of 80.79% and a negative net margin of 16,238.91%. During the same period last year, the business earned ($1.92) earnings per share. Research analysts anticipate that Inovio Pharmaceuticals will post -4.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in INO. Susquehanna Fundamental Investments LLC bought a new position in Inovio Pharmaceuticals during the 1st quarter valued at $1,482,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Inovio Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 6,148 shares during the period. Keystone Financial Group boosted its stake in Inovio Pharmaceuticals by 11.7% during the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 12,840 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Inovio Pharmaceuticals during the third quarter worth about $178,000. Finally, Pathstone Family Office LLC raised its position in Inovio Pharmaceuticals by 344.2% in the third quarter. Pathstone Family Office LLC now owns 148,392 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 114,989 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Featured Articles

• Five stocks we like better than Inovio Pharmaceuticals
• Where to Find Earnings Call Transcripts
• How to Buy the Dip and Sell the Rip on Your Stocks with Options
• Upcoming IPO Stock Lockup Period, Explained
• 3 Hot Buyback Plans Supporting Price Action in 2024
• ETF Screener: Uses and Step-by-Step Guide
• Stocks With Subscription Based Revenue Offer Inflation Protection

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.